What is Kimia?
Kimia Therapeutics is at the forefront of pharmaceutical innovation, developing a next-generation drug discovery engine. By integrating high-throughput chemistry and screening with advanced computational methodologies, the company aims to significantly accelerate the identification and development of novel therapeutic agents. This approach positions Kimia to address unmet medical needs through expedited drug discovery.
How much funding has Kimia raised?
Kimia has raised a total of $55M across 1 funding round:
Series A
$55M
Series A (2023): $55M with participation from Horizons Ventures and The Column Group
Key Investors in Kimia
Horizons Ventures
Horizons Ventures is a prominent investment firm focused on deep science and technology that aims to advance humanity. They support innovative projects with transformative potential, particularly in the science and technology sectors.
The Column Group
The Column Group is a venture ecosystem dedicated to advancing life sciences innovation. They have a proven track record of funding and supporting early-stage technology platforms and later-stage programs, aiming to generate significant returns through therapeutic breakthroughs.
What's next for Kimia?
The substantial enterprise-level funding, particularly the recent major strategic investment, signals a pivotal phase for Kimia. This capital infusion is expected to fuel the expansion of its drug discovery engine, enhance its computational capabilities, and potentially broaden its pipeline of novel drug candidates. The company is poised to leverage this financial momentum to accelerate its mission of bringing innovative therapies to market, marking a critical step in its growth trajectory.
See full Kimia company page
